Thursday, April 24, 2014
Publication and contact
Homeobox C10 (HOXC10)
In vitro and mouse studies suggest decreasing HOXC10
methylation could help treat breast cancers resistant to aromatase
inhibitors and other estrogen-depleting therapies. In human breast cancer
cell lines, silencing HOXC10 via histone and DNA hypermethylation was
associated with resistance to estrogen deprivation. In an estrogen-deprived
mouse xenograft model of breast cancer, silencing HOXC10 expression
increased tumor growth compared with unmodified HOXC10 expression. In
patients with breast cancer who received aromatase inhibitor therapy,
recurrent tumors had lower HOXC10 protein levels than primary tumors. Future
studies could include testing aromatase inhibitors and DNA hypomethylating
agents in mouse models of breast cancer.
Celgene Corp., Pfizer
Inc. and Nippon
Shinyaku Co. Ltd. market Vidaza
a hypomethylating agent that inhibits DNA
methyltransferase, to treat myelodysplastic syndrome (MDS).
Celgene and Pfizer market Vidaza to treat acute myelogenous leukemia (AML).
Otsuka Pharmaceutical Co. Ltd.,
Co. Ltd. and Johnson
& Johnson market Dacogen
a hypomethylating agent that inhibits DNA methyltransferase, to treat MDS and
Celgene has CC-486,
an oral formulation of azacitidine, in
Phase II trials to treat MDS and Phase I testing to treat solid tumors.
Published online April 24, 2014
Patent and licensing status
Pathiraja, T.N. et al.
Sci. Transl. Med.; published online March 26, 2014;
Contact: Steffi Oesterreich, Women's
Cancer Research Center at the University of Pittsburgh, Pittsburgh, Pa.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]